19 this month. Enjoy!
Tjagvad C, Skurtveit S, Linnet K, Andersen LV, Christoffersen DJ, Clausen T.
Eur Addict Res. 2016 Jun 1;22(5):249-258. [Epub ahead of print]
Comments: Patients on very high doses of methadone or also using benzodiazepines were at higher risk of death.
2) Heroin use.
Salani DA, Zdanowicz M, Joseph L.
J Psychosoc Nurs Ment Health Serv. 2016 Jun 1;54(6):30-7. doi: 10.3928/02793695-20160518-05.
Comments: Epidemiologic review.
3) Academic physicians' and medical students' perceived barriers toward bystander administered naloxone as an overdose prevention strategy.
Gatewood AK, Van Wert MJ, Andrada AP, Surkan PJ.
Addict Behav. 2016 May 17;61:40-46. doi: 10.1016/j.addbeh.2016.05.013. [Epub ahead of print]
Comments: Qualitative interviews with medical providers.
4) Patient Characteristics and Outcomes in Unintentional, Non-fatal Prescription Opioid Overdoses: A Systematic Review.
Elzey MJ, Barden SM, Edwards ES.
Pain Physician. 2016 May;19(4):215-28.
Comments: Non-fatal events are far more common, not well-predicted by risk factors, and in need of additional research.
5) Incorporation of poison center services in a state-wide overdose education and naloxone distribution program.
Doyon S, Benton C, Anderson BA, Baier M, Haas E, Hadley L, Maehr J, Rebbert-Franklin K, Olsen Y, Welsh C.
Am J Addict. 2016 Jun;25(4):301-6. doi: 10.1111/ajad.12384. Epub 2016 May 24.
Comments: Interesting case series of naloxone reversals reported to poison control. They report a 75.6% “response rate” although some of the remainder was “unknown” and was there were only 2 deaths among 78 cases, suggesting a rate closer to 97.5%. Response rate to heroin was higher than for prescription opioids. Of the 43 suspected heroin events, 31 went to the ED, 25 were discharged, and 5 required ICU care. Of 31 suspected prescription opioid 20 went to the ED, 9 were discharged, and 6 required ICU care. This is consistent with the more complicated nature of prescription opioid overdose.
Fisher R, O'Donnell D, Ray B, Rusyniak D.
Prehosp Emerg Care. 2016 May 24:1-6. [Epub ahead of print]
Comments: About a 65% response rate among 117 administrations and 1 combative individual.
7) Pharmacotherapy for opioid dependence in jails and prisons: research review update and future directions.
Sharma A, O'Grady KE, Kelly SM, Gryczynski J, Mitchell SG, Schwartz RP.
Subst Abuse Rehabil. 2016 Apr 27;7:27-40. doi: 10.2147/SAR.S81602. eCollection 2016. Review.
Comments: Overdose morality is through the roof when people leave correctional settings. Starting medications in-house is critical.
8) Confronting the HIV, Tuberculosis, Addiction, and Incarceration Syndemic in Southeast Asia: Lessons Learned from Malaysia.
Culbert GJ, Pillai V, Bick J, Al-Darraji HA, Wickersham JA, Wegman MP, Bazazi AR, Ferro E, Copenhaver M, Kamarulzaman A, Altice FL.
J Neuroimmune Pharmacol. 2016 May 24. [Epub ahead of print] Review.
Comments: Managing syndemics in Malaysia.
9) Qualitative assessment of take-home naloxone program participant and law enforcement interactions in British Columbia.
Deonarine A, Amlani A, Ambrose G, Buxton JA.
Harm Reduct J. 2016 May 21;13(1):17. doi: 10.1186/s12954-016-0106-1.
Comments: Interesting qualitative study of drug users and police regarding naloxone.
Zhou Y, Luo W, Cao XB, Zhang B, Wu ZY.
Zhonghua Liu Xing Bing Xue Za Zhi. 2016 May 10;37(5):648-52. doi: 10.3760/cma.j.issn.0254-6450.2016.05.012. Chinese.
Comments: 42% had ever overdosed and 16% had done so in the past year, a relatively low rate.
Bauer LK, Brody JK, León C, Baggett TP.
J Health Care Poor Underserved. 2016;27(2):846-59. doi: 10.1353/hpu.2016.0075.
Comments: Of 219 homeless individuals who died of overdose in Boston, 81% of deaths involved opioids, 85% of decedents had substance use disorders, 61% had psychiatric illness, 45% had chronic pain, and 32% had all three of those issues. This is really complex clinical care.
12) The SOMATICS collaborative: Introduction to a National Institute on Drug Abuse cooperative study of pharmacotherapy for opioid treatment in criminal justice settings.
Chandler RK, Finger MS, Farabee D, Schwartz RP, Condon T, Dunlap LJ, Zarkin GA, McCollister K, McDonald RD, Laska E, Bennett D, Kelly SM, Hillhouse M, Mitchell SG, O'Grady KE, Lee JD.
Contemp Clin Trials. 2016 May;48:166-72. doi: 10.1016/j.cct.2016.05.003. Epub 2016 May 11.
Comments: Extended-release naltrexone studies.
13) Identifying mortality risks in patients with opioid use disorder using brief screening assessment: Secondary mental health clinical records analysis.
Bogdanowicz KM, Stewart R, Chang CK, Downs J, Khondoker M, Shetty H, Strang J, Hayes RD.
Drug Alcohol Depend. 2016 Jul 1;164:82-8. doi: 10.1016/j.drugalcdep.2016.04.036. Epub 2016 May 6.
Comments: Overdose death was associated with unsafe injecting and clinically-appraised suicidality.
McDonald RD, Tofighi B, Laska E, Goldfeld K, Bonilla W, Flannery M, Santana-Correa N, Johnson CW, Leibowitz N, Rotrosen J, Gourevitch MN, Lee JD.
Contemp Clin Trials. 2016 May 10. pii: S1551-7144(16)30059-3. doi: 10.1016/j.cct.2016.05.002. [Epub ahead of print]
Comments: Description of a planned study.
15) Opioid Overdose Prevention Through Pharmacy-based Naloxone Prescription Program: Innovations in Healthcare Delivery.
Bachyrycz A, Shrestha S, Bleske BE, Tinker D, Bakhireva LN.
Subst Abus. 2016 May 10:0. [Epub ahead of print]
Comments: First paper I’ve seen on the uptake of naloxone from pharmacies. Promising data!
Nielsen S, Larance B, Degenhardt L, Gowing L, Kehler C, Lintzeris N.
Cochrane Database Syst Rev. 2016 May 9;5:CD011117. doi: 10.1002/14651858.CD011117.pub2. Review.
Comments: Agonist treatment works, maintenance is best.
Am J Health Syst Pharm. 2015 Sep 1;72(17):1426-7. doi: 10.2146/news150056. No abstract available.
Comments: Nothing new here. Unfortunately, for the most effective approach – giving the medication away at low-threshold programs – the cost needs to be in the low single digits.
18) Opioid Use Trajectories, Injection Drug Use, and Hepatitis C Virus Risk Among Young Adult Immigrants from the Former Soviet Union Living in New York City.
Guarino H, Marsch LA, Deren S, Straussner SL, Teper A.
J Addict Dis. 2015;34(2-3):162-77. doi: 10.1080/10550887.2015.1059711.
Comments: Many participants got syringes only from a pharmacy to avoid being “outed” as a drug injector and did not receive any information about overdose – or other safety messaging – from that source.
19) Opioid abuse in the United States and Department of Health and Human Services actions to address opioid-drug-related overdoses and deaths.
U S Department Of Health And Human Services.
J Pain Palliat Care Pharmacother. 2015 Jun;29(2):133-9. doi: 10.3109/15360288.2015.1037530.